Should Pharma take the M&A cure?

What's Big Pharma's best hope for weathering the next few years of expiring patents and patchy pipelines? M&A, says London's Financial Times. That's not exactly revolutionary, of course; there were almost 1,000 deals in pharma/healthcare for the first half of 2007, according to Pricewaterhouse Coopers. But the Financial Times fingers a few potential acquisition targets, including U.S.-based Sepracor and the UK's Shire Pharmaceuticals.

But not so fast: The newspaper also notes that Merck has steadily improved its lot by avoiding acquisitions. Pfizer, on the other hand, bought Warner-Lambert and Pharmacia, becoming the world's largest drug maker by sales. Whose stock has performed best? Merck's. Maybe bigger isn't better.

- read the M&A report from the Financial Times
- check out the Merck v. Pfizer article

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.